Please assess the completion status of the following clinical trial:

Trial Title: MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old.~2. Able to provide informed consent, or have a caregiver able to provide consent~3. Meets the definition of non-severe recurrent CDI (see Section 2.1, above) AND~4. Has had a positive stool test for C. difficile within 60 days of enrolment~5. Able to undergo colonoscopy and enemas~6. Not pregnant~7. Willing to participate in follow up as part of the study~In addition, the patient must agree to undergo stool testing and blood screening tests that are part of the study, including hepatitis and HIV testing~Exclusion Criteria:~1. Life expectancy \< 6 months~2. Evidence of severe CDI ((neutropenia (ANC\<1000) or WBC\>30, creatinine \>2X baseline, presence of toxic megacolon or intestinal perforation, admission to ICU)~3. History of chronic diarrhea~4. Need for regular use of agents that affect GI motility (narcotics such as codeine or morphine, agents such as loperamide or metoclopramide)~5. Use of antibiotics for another infection (other than CDI)~6. Colostomy~7. Elective surgery that will require preoperative antibiotics planned within 6 months of enrolment~8. Pregnant or planning to get pregnant in the next 6 months~9. Unable to tolerate MET-2 for any reason~10. Any condition for which colonoscopy or enema may be contraindicated (e.g., neutropenia, thrombocytopenia, bleeding disorders, severe colitis, etc)~11. Any condition for which, in the opinion of the investigator, the patient should be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MET-2 Capsules (Type: EXPERIMENTAL): Patients will be on vancomycin to control symptoms up until the time of the treatment.~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..~All patients will be followed up for 120 days after the last treatment has been received.

Based on this trial design, predict the completion outcome and termination type (if applicable).